Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 14, 2026Journal of Cancer Research and Clinical OncologyOpen Access

Survival of esophageal squamous cell carcinoma achieving pathological complete response after neoadjuvant immunochemotherapy

View Full Paper
Ask AI
Bookmark
Share

Authors

ZZZongpu ZhangBLBin LiQHQingyuan Huang

Discussion

Loading...

Member takes

Overview

Observational study reveals favorable survival in esophageal squamous cell carcinoma patients achieving pathological complete response after immunochemotherapy, indicating recurrence risks persist.

Key Points

  • To evaluate survival outcomes and recurrence risks among patients with locally advanced esophageal squamous cell carcinoma who achieved a pathological complete response following neoadjuvant immunochemotherapy.
  • Analyzed data from 154 patients who achieved pathological complete response (pCR) after neoadjuvant immunochemotherapy between January 2020 and June 2025.
  • Documented regimens including chemotherapy combined with pembrolizumab (30.5%), tislelizumab (24.0%), sintilimab (20.1%), camrelizumab (16.9%), or other immune checkpoint inhibitors (8.4%), followed by McKeown or Ivor Lewis resection.
  • Evaluated disease-free survival (DFS) as the primary endpoint alongside overall survival (OS) over a median follow-up of 25 months.
  • 1-year and 3-year disease-free survival rates were 97% and 78%, respectively, while 1-year and 3-year overall survival rates were 97% and 88%, respectively.
  • Reduced disease-free survival was significantly associated with advanced clinical tumor stage (HR = 4.831, 95% CI 1.748–13.347, P = 0.002) and receiving more than two treatment cycles (HR = 3.449, 95% CI 1.168–10.179, P = 0.025).
  • A treatment-to-surgery interval of less than 6 weeks also independently predicted poorer DFS (HR = 5.344, 95% CI 1.198–23.840, P = 0.028).

Cite This Study

Zhang et al. (2026) studied this question.

synapsesocial.com/papers/6a7ee587b70b84ec8b914745https://doi.org/10.1007/s00432-026-06587-6
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1474. NEOADJUVANT CHEMOIMMUNOTHERAPY VERSUS CHEMOTHERAPY PLUS ESOPHAGECTOMY FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA: PRIMARY RESULT OF A RANDOMIZED CLINICAL TRIAL2025
  2. 2Comparative study of the tumor-infiltrating lymphocytes before and after neoadjuvant chemoimmunotherapy in esophageal squamous cell carcinoma2026
  3. 3Analysis of factors affecting complete pathological remission after neoadjuvant immunocombination chemotherapy treatment for locally advanced esophageal squamous carcinoma.2024
  4. 4A randomized controlled study on perioperative treatment of esophageal squamous cell carcinoma with camrelizumab combined with nab-paclitaxel and cisplatin.2024
  5. 5Neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma in real-world practice: an analysis of the clinical outcomes and long-term survival, and the feasibility of using major pathological response as a surrogate endpoint2025 · 3 citations